Metropolitan Life Insurance Company (MetLife)’s 4D Molecular Therapeutics FDMT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,164	Closed	-$68.9K	–	750
2024 Q1	$68.9K	Sell	2,164 -448	-17%	-$11.4K	﹤0.01%	1249
2023 Q4	$52.9K	Hold	2,612	–	–	﹤0.01%	1421
2023 Q3	$33.3K	Buy	2,612 +850	+48%	+$14.2K	﹤0.01%	1623
2023 Q2	$31.8K	Hold	1,762	–	–	﹤0.01%	1682
2023 Q1	$30.3K	Sell	1,762 -325	-16%	-$6.32K	﹤0.01%	1679
2022 Q4	$46.4K	Hold	2,087	–	–	﹤0.01%	1520
2022 Q3	$16.8K	Hold	2,087	–	–	﹤0.01%	2107
2022 Q2	$14.6K	Hold	2,087	–	–	﹤0.01%	2198
2022 Q1	$31.6K	Sell	2,087 -6,197	-75%	-$97.3K	﹤0.01%	1855
2021 Q4	$182K	Buy	8,284 +2,247	+37%	+$55.1K	﹤0.01%	2092
2021 Q3	$163K	Buy	+6,037	New	+$172K	﹤0.01%	2235
2021 Q2	–	Sell	-2,984	Closed	-$129K	–	2762
2021 Q1	$129K	Buy	+2,984	New	+$132K	﹤0.01%	2305

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s FDMT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of 4D Molecular Therapeutics (FDMT) in Q2 2024, closing a stake of 2,164 shares — an estimated $68.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in FDMT in Q1 2021 and held it in 12 quarters. The position peaked at $182K in Q4 2021. 143 funds tracked by Wall St. Rank hold FDMT as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining 4D Molecular Therapeutics position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,164 4D Molecular Therapeutics shares in Q2 2024, an estimated $68.9K.
Metropolitan Life Insurance Company (MetLife) first reported a position in 4D Molecular Therapeutics in Q1 2021 and held it in 12 quarters.
Metropolitan Life Insurance Company (MetLife)'s 4D Molecular Therapeutics position peaked at $182K in Q4 2021.
143 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.